Replimune Shares Jump 15% After Kennedy Comment

Replimune Group shares rose 15% on April 22, 2026 after Health Secretary Robert F. Kennedy Jr. distanced himself from the FDA rejection of RP1.
The FDA earlier this month rejected RP1 for advanced skin cancer, citing reliance on a single‑arm study and demanding a well‑controlled trial.
The stock had fallen nearly 70% since the second FDA rejection in two years, but rallied after a Wall Street Journal piece questioned Kennedy’s comments.
FDA drug head Vinay Prasad is slated to leave the agency in April, as noted in the WSJ article.